Glycosylation in Cancer Medicines Delivery and Their Patents.

IF 3
Biswa Mohan Sahoo, Shikha Sharma, Payal Bhatnagar, Gaurav Kant Saraogi, Bimal Krishna Banik
{"title":"Glycosylation in Cancer Medicines Delivery and Their Patents.","authors":"Biswa Mohan Sahoo, Shikha Sharma, Payal Bhatnagar, Gaurav Kant Saraogi, Bimal Krishna Banik","doi":"10.2174/0115672018396720251204111343","DOIUrl":null,"url":null,"abstract":"<p><p>Glycosylation plays a significant part in cancer pathophysiology, shaping tumour progression, metastasis, immune evasion, and drug resistance. Aberrant glycosylation patterns in tumours serve as impending biomarkers and therapeutic targets for enriched cancer diagnostics and treatment strategies. Developments in glycosylation-mediated drug delivery systems (DDSs) have enabled more targeted targeting of tumour cells through receptor-specific interactions, boosting drug efficacy while mitigating systemic toxicity. Glycosylated nanocarriers, antibodies, and fusion proteins have proven favourable applications in anticancer therapies, improving drug stability, cellular uptake, and immune modulation. Recent patents focus on innovative advances leveraging glycosylation to improve drug targeting, stability, and therapeutic efficacy, predominantly in addressing multidrug resistance in cancers such as non-small cell lung cancer, breast cancer, and prostate cancer. Narrative review, synthesizing published research and patents related to glycosylation-mediated drug delivery for cancer. Peer-reviewed journal articles and patents retrieved from European, Google Patents, and Lens.org databases (2020-2025) using keywords such as <i>cancer, glycosylation, drug, medicine, oncology</i>. Covers glycosylation biology in cancer, receptor-mediated targeting, applications in nanocarriers and antibodies, roles in metastasis, immune evasion, metabolism, ferroptosis, senescence, biomarkers, and delivery systems. Qualitative synthesis of literature findings and patent specifications, categorizing them by therapeutic approach, target, stage of development, and potential for clinical translation. Identification of trends, challenges, and future perspectives in glycosylation-based drug delivery. This review surveys the structural and functional aspects of glycosylation in cancer biology, its effects on tumour behaviour, and its emerging role in personalised medicine through glycosylation-based diagnostics and targeted therapeutics.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115672018396720251204111343","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Glycosylation plays a significant part in cancer pathophysiology, shaping tumour progression, metastasis, immune evasion, and drug resistance. Aberrant glycosylation patterns in tumours serve as impending biomarkers and therapeutic targets for enriched cancer diagnostics and treatment strategies. Developments in glycosylation-mediated drug delivery systems (DDSs) have enabled more targeted targeting of tumour cells through receptor-specific interactions, boosting drug efficacy while mitigating systemic toxicity. Glycosylated nanocarriers, antibodies, and fusion proteins have proven favourable applications in anticancer therapies, improving drug stability, cellular uptake, and immune modulation. Recent patents focus on innovative advances leveraging glycosylation to improve drug targeting, stability, and therapeutic efficacy, predominantly in addressing multidrug resistance in cancers such as non-small cell lung cancer, breast cancer, and prostate cancer. Narrative review, synthesizing published research and patents related to glycosylation-mediated drug delivery for cancer. Peer-reviewed journal articles and patents retrieved from European, Google Patents, and Lens.org databases (2020-2025) using keywords such as cancer, glycosylation, drug, medicine, oncology. Covers glycosylation biology in cancer, receptor-mediated targeting, applications in nanocarriers and antibodies, roles in metastasis, immune evasion, metabolism, ferroptosis, senescence, biomarkers, and delivery systems. Qualitative synthesis of literature findings and patent specifications, categorizing them by therapeutic approach, target, stage of development, and potential for clinical translation. Identification of trends, challenges, and future perspectives in glycosylation-based drug delivery. This review surveys the structural and functional aspects of glycosylation in cancer biology, its effects on tumour behaviour, and its emerging role in personalised medicine through glycosylation-based diagnostics and targeted therapeutics.

肿瘤药物传递中的糖基化及其专利。
糖基化在肿瘤病理生理、形成肿瘤进展、转移、免疫逃避和耐药性中起着重要作用。肿瘤中的异常糖基化模式作为即将到来的生物标志物和治疗靶点,丰富了癌症诊断和治疗策略。糖基化介导的药物传递系统(dds)的发展使得通过受体特异性相互作用更有针对性地靶向肿瘤细胞,提高药物疗效,同时减轻全身毒性。糖基化纳米载体、抗体和融合蛋白已被证明在抗癌治疗、改善药物稳定性、细胞摄取和免疫调节方面有良好的应用。最近的专利集中于利用糖基化来提高药物靶向性、稳定性和治疗效果的创新进展,主要用于解决非小细胞肺癌、乳腺癌和前列腺癌等癌症的多药耐药问题。综述、综合糖基化介导的癌症药物传递相关的已发表研究和专利。从欧洲、谷歌专利和Lens.org数据库(2020-2025)检索同行评议的期刊文章和专利,关键词为癌症、糖基化、药物、医学、肿瘤学。涵盖癌症中的糖基化生物学,受体介导的靶向,纳米载体和抗体的应用,在转移,免疫逃避,代谢,铁死亡,衰老,生物标志物和传递系统中的作用。定性综合文献发现和专利说明书,根据治疗方法、靶点、发展阶段和临床转化潜力对其进行分类。确定以糖基化为基础的给药的趋势、挑战和未来前景。本文综述了糖基化在癌症生物学中的结构和功能方面,它对肿瘤行为的影响,以及它通过基于糖基化的诊断和靶向治疗在个体化医学中的新兴作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书